- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2014 (2014), Article ID 575423, 5 pages
Promotive Effect of Topical Ketoconazole, Minoxidil, and Minoxidil with Tretinoin on Hair Growth in Male Mice
1Department of Dermatology, Kufa College of Medicine, Kufa, Iraq
2Department of Pharmacology and Therapeutics, Kufa College of Medicine, Kufa, Iraq
Received 2 December 2013; Accepted 23 January 2014; Published 9 March 2014
Academic Editors: R. Thurmond, R. Villalobos-Molina, and S.-N. Wu
Copyright © 2014 Muhsin A. Aldhalimi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Recently topical use of 2% Ketoconazole solution has been reported to have a therapeutic effect on androgenic alopecia. Minoxidil is a vasodilatory medication used primarily as antihypertensive drug. It was discovered to have the side effect of hair growth and reversing baldness. Tretinoin is commonly used topically for acne treatment and in the treatment of photoaging. It is used by some as hair loss treatment. Objective. To compare the stimulatory effect of Ketoconazole, Minoxidil, and Minoxidil with Tretinoin on hair growth in a mouse model. Materials and Methods. Coat hairs on the dorsal skin of seven weeks old male mice were gently clipped and then stained by using commercial dye. These mice were divided into four groups each of five treated with topical application of ethanol 95%, Ketoconazole solution 2%, Minoxidil solution 5%, and Minoxidil with Tretinoin solution 0.1%, respectively. The drugs were applied once daily for three weeks, the clipped area was photographed, and the ratio of regrown coat area was calculated. Results. The results demonstrated that Ketoconazole, Minoxidil, and Minoxidil with Tretinoin had a significant stimulatory effect on hair growth compared with the control group and Minoxidil was the most effective drug among them.
Androgenic alopecia is a partial or complete loss of hair that occurs in a progressive pattern in genetically predisposed individuals . A variety of genetic and environmental factors likely play a role in androgenic alopecia, and most of contributing factors remain unknown.
The age at onset of androgenic alopecia differs but occurs usually in mid-twenties. The prevalence and severity of androgenic alopecia increase directly with age . The basis of androgenic alopecia is a progressive decrease in the density of terminal hairs and concurrent increase in density of vellus hairs . In effect, terminal hairs are turned off and are transformed into vellus hairs, and this effect is due to hair follicle miniaturization , which is associated with substantial reduction in hair diameter. Although the mechanisms of these changes have not been established definitively, male pattern baldness is known to depend on androgens, in particular the dihydrotestosterone DHT . DHT is synthesized from testosterone by 5-reductase enzyme type-1 and type-2, and these enzymes are found on the nuclear membranes .
Ketoconazole (KCZ) is an imidazole antifungal agent. Long term use of 2% KCZ was reported to be effective against androgenic alopecia in patients without seborrheic dermatitis and dandruff . Minoxidil is a vasodilatory medication used primarily as antihypertensive drug. Minoxidil is a potassium channel agonist that has the chemical structure of nitric oxide (NO), a blood vessel dilator, and may be a nitric oxide agonist. This appears to explain its vasodilatory effect  but may also be linked to Minoxidil’s ability to stimulate hair growth and treat hair loss.
Tretinoin is the acid form of vitamin A, also known as all transretinoic acid (ATRA), helps normalize hyperkeratinization, and has demonstrated significant anti-inflammatory effects. It is used by some as hair loss treatment .
2. Materials and Methods
The study was conducted on 20 mature male Albino-Webster mice, which were housed in the air-conditioned animal house of College of Medicine, University of Kufa, with standard animal diet and water. Their ages ranged from 6 to 7 weeks, and their weights ranged from 25 to 30 gm. The design of the study was approved by the local ethical committee in the College of Medicine, University of Kufa.
2.2.1. Clipping of the Coat Hair of Mice
One day before the experiment, the mice were anesthetized with diethyl ether, and the coat hair on the dorsal skin was gently clipped using an electric shaver to avoid injury. The skin surface of the clipped area of each mouse was observed on the day when the materials were to be applied to have a pinkish color, suggesting that it was in the resting phase . Mice were randomly chosen and put into four groups, each group included five mice, and they had been photographed (Figure 1).
The denuded area of the dorsal skin of each mouse was stained by using commercial dye (Hoffmann, 2001, 2003) [11, 12]; then it was washed by using alcohol, staining done to find the ratio of area showing hair regrowth (area of white color) to the ratio of area denuded of hair (area of black color). After staining of mice, also they had been photographed (Figure 2).
2.2.3. Study Groups
Group I was considered as a control group and treated with the vehicle solution (95%), ethanol alcohol, 0.1 mL applied by a micropipette to the denuded skin and then spread by means of swab once daily 6 days/weak for 3 weeks.
Group II was treated with Ketoconazole solution 2%, 0.1 mL applied to the denuded skin by a micropipette once daily for 3 weeks.
Group III was treated with Minoxidil solution 5%, 0.1 mL applied to the denuded skin by a micropipette once daily for 3 weeks.
Group IV was treated with equal amounts of Minoxidil solution 5% + Tretinoin 0.1%, 0.1 mL of each of them applied by a micropipette once daily for 3 weeks.
The mice were macroscopically observed and photographed every week until the 21st day.
Photographic Data Analysis. Photographic data were analyzed by a special computer program called Photoshop Visual Basic-8 program. This program calculated the ratio of the area showing hair regrowth (which was represented by the area of white color) to the ratio of the area denuded of hair (which was represented by the area of black color), and this was done for each mouse in the four groups.
2.3. Histological Sections
After completing the treatment for three weeks, histological sections were obtained. These sections were examined microscopically for the hair follicle number and diameter, in control and treated groups.
2.4. Statistical Analysis
Statistical analysis was done by using one-way ANOVA test with post hoc test at level of significance to compare between control and treated groups and then performing multiple comparisons between the treated groups.
Chi-square test had been used to compare between the proportion of histological changes in various groups.
The histological examination of the specimens showed no significant increase in the number of hair follicles ( value > 0.05) in all treatment groups, while hair follicle diameter has been increased significantly ( value < 0.05) in all treatment groups (Tables 3, 4, and 5 and Figures 7, 8, 9, and 10).
This study demonstrated that topical Ketoconazole stimulates hair growth significantly. This result is in agreement with Piérard-Franchimont et al. , Khandpur et al. , Jiang et al. , Inui and Itami , and Hugo Perez .
The efficacy of 2% KCZ shampoo in androgenic alopecia patients appeared to stem from its antiandrogenic properties [16, 17]. However, our study demonstrated that topical KCZ was effective on the androgen-insensitive coat hairs of mice, so KCZ behaved as an androgen-independent biological response modifier. However, its action on hair growth and hair follicle diameter is less than that of Minoxidil.
Minoxidil induces rapid relaxation of vascular smooth muscle induced by its sulphated metabolite, Minoxidil sulphate . The conversion of Minoxidil to Minoxidil sulphate is catalysed by sulphotransferase enzyme, which was initially demonstrated in rat liver  and has since been found in human liver , platelets , and mouse vibrissae follicles .
In scalp skin of stump-tailed macaque, sulphotransferase activity is largely localized in the hair follicle . Biochemical evidence for Minoxidil sulphation by two phenol sulphotransferases has been found in human scalp skin .
There are individual variations in scalp sulphotransferase activity and this correlates with the level in platelets . In a clinical setting scalp sulphotransferase activity was higher in men who responded to Minoxidil compared with those who did not respond .
Tretinoin is known to alter cell proliferation and differentiation and may promote vascular proliferation, and these actions may be important to hair growth and so affect hair follicle during the various growth and regression phases.
Preliminary studies of cRABP levels in whole scalp skin of human subjects with male pattern baldness indicated that, in the scalp areas not normally affected by alopecia, levels of cRABPs were higher than in areas with alopecia, and the levels of cRABPs in whole skin were increased by topical application of retinoic acid .
It has been found that combining high concentration of retinoic acid with Minoxidil causes less elongation than at low concentration suggested that retinoic acid might increase the tissue concentration of Minoxidil in hair follicles .
Tretinoin was reported to increase percutaneous absorption of Minoxidil by increasing the stratum corneum permeability . Our study demonstrated that Tretinoin in combination with Minoxidil caused a significant increase in hair growth and a significant increase in hair follicle diameter. However, in this study the results obtained from the combination of Minoxidil with low dose Tretinoin are less than that of Minoxidil alone and this warrants further studies to evaluate the role of Tretinoin in combination with Minoxidil in the treatment of hair loss.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
- R. Sinclair, “Fortnightly review. Male pattern androgenetic alopecia,” British Medical Journal, vol. 317, no. 7162, pp. 865–869, 1998.
- J. B. Hamilton, “Patterned loss of hair in man; types and incidence,” Annals of the New York Academy of Sciences, vol. 53, no. 3, pp. 708–728, 1951.
- D. A. Whiting, “Male pattern hair loss: current understanding,” International Journal of Dermatology, vol. 37, no. 8, pp. 561–566, 1998.
- D. A. Whiting, “Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss,” Journal of the American Academy of Dermatology, vol. 45, no. 3, pp. S81–S86, 2001.
- J. A. Ellis, R. Sinclair, and S. B. Harrap, “Androgenetic alopecia: pathogenesis and potential for therapy,” Expert Reviews in Molecular Medicine, vol. 4, pp. 1–11, 2002.
- G. Bartsch, R. S. Rittmaster, and H. Klocker, “Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia,” European Urology, vol. 37, no. 4, pp. 367–380, 2000.
- C. Piérard-Franchimont, P. De Doncker, G. Camvenbergh, and G. E. Pierard, “Ketoconazole shampoo: effect of long-term use in androgenic alopecia,” Dermatology, vol. 196, no. 4, pp. 474–477, 1998.
- K. D. Meisheri, L. A. Cipkus, and C. J. Taylor, “Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability,” Journal of Pharmacology and Experimental Therapeutics, vol. 245, no. 3, pp. 751–760, 1988.
- N. K. Terezakis and G. S. Bazzano, “Retinoids: compounds important to hair growth,” Clinics in Dermatology, vol. 6, no. 4, pp. 129–131, 1988.
- H. Ogawa and M. Hattori, “Regulation mechanisms of hair growth,” in Normal and Abnormal Epidermal Differentiation, M. Seiji and I. A. Bernstein, Eds., pp. 159–170, University of Tokyo Press, Tokyo, Japan, 1983.
- R. Hoffmann, “TrichoScan: combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo,” European Journal of Dermatology, vol. 11, no. 4, pp. 362–368, 2001.
- R. Hoffmann, “TrichoScan: a novel tool for the analysis of hair growth in vivo,” Journal of Investigative Dermatology Symposium Proceedings, vol. 8, no. 1, pp. 109–115, 2003.
- S. Khandpur, M. Suman, and B. S. Reddy, “Comparative efficacy of various treatment regimens for androgenetic alopecia in men,” Journal of Dermatology, vol. 29, no. 8, pp. 489–498, 2002.
- J. Jiang, R. Tsuboi, Y. Kojima, and H. Ogawa, “Topical application of ketoconazole stimulates hair growth in C3H/HeN mice,” Journal of Dermatology, vol. 32, no. 4, pp. 243–247, 2005.
- S. Inui and S. Itami, “Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity,” Journal of Dermatological Science, vol. 45, no. 1, pp. 66–68, 2007.
- B. S. Hugo Perez, “Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men,” Medical Hypotheses, vol. 62, no. 1, pp. 112–115, 2004.
- A. W. Rafi and R. M. Katz, “Pilot study of 15 patients receiving a new treatment regimens for androgenic alopecia: the effects of atopy on androgenic alopecia,” ISRN Dermatology, vol. 2011, Article ID 241953, 11 pages, 2011.
- E. A. Olsen, M. S. Weiner, E. R. Delong et al., “Topical minoxidil in early male pattern baldness,” Journal of the American Academy of Dermatology, vol. 82, pp. 90–93, 1984.
- V. C. Weiss, D. P. West, and C. E. Mueller, “Topical minoxidil in alopecia areata,” Journal of the American Academy of Dermatology, vol. 5, no. 2, pp. 224–226, 1981.
- O. Mori and H. Uno, “The effect of topical minoxidil in the bald stump tailed macaque,” Journal of the American Academy of Dermatology, vol. 17, pp. 276–281, 1990.
- G. A. Johnson, K. J. Barsuhn, and J. M. McCall, “Sulfation of minoxidil by liver sulfotransferase,” Biochemical Pharmacology, vol. 31, no. 18, pp. 2949–2954, 1982.
- C. N. Falany and E. A. Kerl, “Sulfation of minoxidol by human liver phenol sulfotransferase,” Biochemical Pharmacology, vol. 40, no. 5, pp. 1027–1032, 1990.
- G. A. Johnson and C. A. Baker, “Sulfation of minoxidil by human platelet sulfotransferase,” Clinica Chimica Acta, vol. 169, no. 2-3, pp. 217–227, 1987.
- A. E. Buhl, D. J. Waldon, C. A. Baker, and G. A. Johnson, “Minoxidil sulfate is the active metabolite that stimulates hair follicles,” Journal of Investigative Dermatology, vol. 95, no. 5, pp. 553–557, 1990.
- C. A. Baker, H. Uno, and G. A. Johnson, “Minoxidil sulfation in the hair follicle,” Skin Pharmacology, vol. 7, no. 6, pp. 335–339, 1994.
- R. J. Anderson, P. E. Kudlacek, and D. L. Clemens, “Sulfation of minoxidil by multiple human cytosolic sulfotransferases,” Chemico-Biological Interactions, vol. 109, no. 1–3, pp. 53–67, 1998.
- A. E. Buhl, C. A. Baker, A. J. Dietz et al., “Minoxidil sulfotransferase activity influences the efficacy of Rogaine topical solution: enzyme studies using scalp and platelets,” Journal of Investigative Dermatology, vol. 102, article 534, 1994.
- G. Bazzano, N. Terezakis, H. Attia et al., “Effect of retinoids on follicular cells,” Journal of Investigative Dermatology, vol. 101, no. 1, pp. 138–142, 1993.
- G. S. Bazzano, N. Terezakis, and W. Galen, “Topical tretinoin for hair growth promotion,” Journal of the American Academy of Dermatology, vol. 15, no. 4, pp. 880–893, 1986.
- G. Bazzano, H. Attia, and N. Terezakis, “Cellular retinoic acid binding protein levels in hair and scalp skin of subjects with alopecia,” Clinical Research, vol. 39, article 558A, 1991.
- S. K. Oh, K. P. Hyun, J. O. Youn et al., “Promotive effect of minoxidil combined with All- trans retinoic acid (tretinoin) on human hair growth in vitro,” Journal of Korean Medical Science, vol. 22, no. 2, pp. 283–289, 2007.
- J. J. Ferry, K. K. Forbes, J. T. VanderLugt, and G. J. Szpunar, “Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution,” Clinical Pharmacology and Therapeutics, vol. 47, no. 4, pp. 439–446, 1990.